SF3B1 and neoplasm: Similarly, newer SF3B1-targeting inhibitors have emerged, including the Sudemycin family and H3B-8800, which demonstrate stronger splicing interference and cytotoxicity in tumor cells with comparatively milder effects on normal cells, indicating potential clinical applicability [333,334].